Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have sh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatol Commun
Main Authors: Wang, Fang, Bank, Thomas, Malnassy, Gregory, Arteaga, Maribel, Shang, Na, Dalheim, Annika, Ding, Xianzhong, Cotler, Scott J., Denning, Mitchell F., Nishimura, Michael I., Breslin, Peter, Qiu, Wei
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983153/
https://ncbi.nlm.nih.gov/pubmed/29881824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1181
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados